Collectionner le produit
Détails du produit
Synonyms
CD32a, FCGR2A, CD32, FCG2 , FCGR2A1, IGFR2
Source
Human CD32a (H167), His Tag (CD1-H5223) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).
Predicted N-terminus: Ala 36
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.5 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human CD32a (H167), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Human CD32a (H167), His Tag (Cat. No. CD1-H5223) is more than 90% and the molecular weight of this protein is around 25-40 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human CD32a (H167), His Tag (Cat. No. CD1-H5223) at 5 μg/mL (100 μL/well) can bind Biotinylated Human C-Reactive Protein, His,Avitag (Cat. No. CRP-H82E4) with a linear range of 0.02-1.25 μg/mL (Routinely tested).
Protocol
Bioactivity-SPR
Immobilized Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 1.45 μM as determined in a SPR assay (Biacore T200) (QC tested).
Protocol
Rituximab immobilized on CM5 Chip can bind Human CD32a (H167), His Tag (Cat. No. CD1-H5223) with an affinity constant of 0.882 μM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 1.30 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
M***i2023-06-15
J'aimeI was very unsure about how to go about ordering this human FC gamma RIAA. I had an experiment planned and knew what my ideal situation was, but didn't quite know how to get there. I discussed with my PI and we reached out to the customer service chat who recommended this product. I needed something already with a His tag that I didn't have to engineer that also had good purity. We tested it recently for the first time and were really impressed with the results. High yield, easy to use, and shipped extremely fast. Was very impressed with the customer service as well. Product was clearly designed to be simple and effective and didn't cost an arm and a leg. Overall, works well and effective for what we needed.
Introduction de fond
There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIMbearing receptors may also be coexpressed and coengaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Low affinity immunoglobulin gamma Fc region receptor II-a
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
2 Détails
- Étape de développement la plus élevée：
Phase 1 Clinical
Contact Us
Drug Candidate Licensing
